Navigation Links
Aspreva and Roche Announce Preliminary Results for Phase III Study,Evaluating CellCept in Lupus Nephritis

pregnancy (see complete product information). Adverse events reported in more than 30% of renal, cardiac or liver transplant patients receiving CellCept (in combination with cyclosporine and corticosteroids) were pain, fever, headache, asthenia, anemia, leucopenia (patients should be monitored for neutropenia; dosing should be interrupted or the dose reduced if neutropenia develops), thrombocytopenia, leukocytosis, urinary tract infection, hypertension, hypotension, peripheral edema, hypercholesteremia, hypokalemia, hyperglycemia, creatinine, BUN and cough increased, hypomagnesemia, diarrhea, constipation, nausea, vomiting, respiratory infection, dyspnea, lung disorder, pleural effusion, tremor and insomnia. Patients receiving immunosuppressant regimens are at increased risk of developing lymphomas and other malignancies, particularly of the skin.

Warning: Increased susceptibility to infection and the possible development of lymphoma may result from immunosuppression. Only physicians experienced in immunosuppressive therapy and management of renal, cardiac or hepatic transplant patients should use CellCept. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.

About Aspreva Pharmaceuticals

Aspreva is a global pharmaceutical company focused on identifying, developing, and, upon approval, commercializing evidence-based medicines for patients living with less common diseases. Aspreva common stock is traded on the NASDAQ Global Select Market under the trading symbol "ASPV" and on the Toronto Stock Exchange under the trading symbol "ASV". Learn more at http://www.aspreva.com.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's lead
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)...  Luminex Corporation (Nasdaq: LMNX ) today announced that ... 2013 on Monday, February 3, 2014. A press release announcing ... trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... highlights and financial results for the fourth quarter and twelve ...
(Date:1/14/2014)... Calif. , Jan. 14, 2014 The Brandeis Medical Center, ... Angeles a premier and affordable laser tattoo removal experience ... Dr. Brandeis, focus is in providing high quality cosmetic services with ... patients. " Southern California has seen ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... QPT: TSX Venture Exchange, EDMONTON, May 02, 2007 ... Quest is pleased to provide an,update on the ... cancer. , Prostate cancer is the second leading ... 230,000 new cases and 30,000 deaths,per year. Current ...
... Mass.--(BUSINESS WIRE)--May 3, 2007 - Xanthus,Pharmaceuticals, Inc ... clinical and pathological signs of chronic,disease in ... presentation,was made by Stephen J. Karlik, Ph.D., ... Western Ontario, London, Ontario,together with researchers from ...
Cached Medicine Technology:Quest PharmaTech's Prostate Cancer Program Update 2Quest PharmaTech's Prostate Cancer Program Update 3Xanthus Presents Novel Approach for Autoimmune Disease Reversal,with Symadex 2Xanthus Presents Novel Approach for Autoimmune Disease Reversal,with Symadex 3
(Date:4/17/2014)... in benign prostate tissue was associated with high-grade, ... found even in those with low prostate-specific antigen ... Cancer Epidemiology, Biomarkers & Prevention , a ... , An analysis of prostate tissue biopsies collected ... the Prostate Cancer Prevention Trial (PCPT) found that ...
(Date:4/17/2014)... CHAMPAIGN, Ill. One of the most popular vaccine ... choice. And doctors may be overlooking some cost factors ... actually a more expensive option, according to a new ... of vaccines to administer can be driven by numerous ... study and a professor of computer science and of ...
(Date:4/17/2014)... AURORA, Colo. (April 17, 2014) Two recent ... Medicine researcher and colleagues may help scientists develop ... virus, Yellow fever, Japanese encephalitis and other disease-causing ... of biochemistry and molecular genetics at the School ... the Howard Hughes Medical Institute, and colleagues recently ...
(Date:4/17/2014)... Rochelle, NY, April 17, 2014U.S. military personnel who ... plus impact" concussive traumatic brain injury (TBI) were ... evacuated for other medical reasons. Differences in measures ... depression 6-12 months after injury are reported in ... a peer-reviewed journal from Mary Ann Liebert, Inc., ...
(Date:4/17/2014)... one in five infants in the United States annually ... several months after birth. Research into probiotic use for ... April 1, 2014 issue of the British Medical ... "Probiotics and Infant Colic," concluding that the use of ... did not reduce crying or fussing in infants ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... Vancouver Residents in cardiac surgery who receive extra training ... get into the operating room, Dr. Buu-Khanh Lam today told ... Stroke Foundation and the Canadian Cardiovascular Society. Dr. ... containing sutures, forceps, and miniature tubing that can be ...
... FRIDAY, Oct. 21 (HealthDay News) -- ,Children with specific ... Concerta), which is widely used to treat attention-deficit hyperactivity ... could help improve treatment of ADHD, according to the ... have a good way of predicting who will experience ...
... at the University of Utah have discovered a new way ... tools for predicting which breast cancers will spread and new ... results are published online today in the journal Nature ... cancer studies, the researchers grafted tumor tissue from consenting breast ...
... blood pressure, improve lifestyle and enhance quality of life, ... "E-counselling has the potential to strengthen ... Dr. Nolan told the Canadian Cardiovascular Congress, which is ... Canadian Cardiovascular Society. "We found that it led to ...
... risk factors for hepatocellular cancer, smoking, obesity, and heavy alcohol ... to a large share of the disease burden in Europe, ... the Journal of the National Cancer Institute. ... C and hepatocellular cancer has been known for a few ...
... , FRIDAY, Oct. 21 (HealthDay News) --,Older ... outpatient surgery and receiving a short-acting anesthetic, according to ... driving abilities were tested on a driving simulator before ... under sedation. The researchers looked at the participants, degree ...
Cached Medicine News:Health News:Heart surgeons-in-training benefit from hands-on homework 2Health News:Some Kids Respond Better to ADHD Drug Than Others 2Health News:Will my breast cancer spread? Discovery may predict probability of metastasis 2Health News:E-counselling shows dramatic results in lowering blood pressure 2Health News:E-counselling shows dramatic results in lowering blood pressure 3Health News:European studies on risks of hepatocellular carcinoma 2Health News:European studies on risks of hepatocellular carcinoma 3Health News:Older Drivers More Cautious Than Younger Ones After Surgery 2
... MICROSTAAR injector contains a plunger style advance, ... be resterilized for multiple use. The injector ... accepts only STAAR cartridges. These injectors are ... This system was designed specifically ...
... the fundamental capsulotmy laser - the unique Ultra ... 2855% less energy in air at approximately 1.8 ... This technology eliminates the occurrence of hot ... pitting. , , , Ultra Q ...
... system is an innovative, robust and ... excellent clinical performance. The digital broadband ... the ES500 system deliver excellent tissue ... system offers a full suite of ...
Protects the eye during or after surgery or trauma. 8mm diameter, lint free keeps cornea moist. Protects retina from operating microscope light rays....
Medicine Products: